Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Sponsor: AstraZeneca

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05771480

Patient View

This study evaluates the safety and efficacy of durvalumab with gemcitabine-based chemotherapy in adults with advanced biliary tract cancers. Eligible participants have unresectable or metastatic BTC, WHO/ECOG PS 0-2, and meet specific health criteria. Interventions include durvalumab and various gemcitabine combinations, with treatment spanning up to 8 cycles, followed by maintenance therapy.

Patient Parameters

Program Overview

A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.

Description

This study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are ≥ 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy. Participants with WHO/ECOG PS 2 will be capped at 20% of the overall treated participant population.

The study consists of 4 periods: screening period (Day-28 to Day -1), treatment period up to 8 cycles of gemcitabine-based chemotherapy regimens with durvalumab, maintenance treatment with durvalumab alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), and then safety and survival follow-up.

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed, unresectable advanced or metastatic biliary tract carcinoma (BTC) including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma, and ampulla of Vater (AoV) carcinoma
  • Participants with unresectable or metastatic BTC
  • A World Health Organisation Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) of 0 to 2
  • At least one lesion that qualifies as a Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) target lesion at baseline
  • Adequate organ and bone marrow function
  • Body weight of > 30 kg
  • Negative pregnancy test (serum) for women of childbearing potential
  • Female participants must be one year post-menopausal (amenorrhoeic for 12 months without an alternative medical cause)
  • Male and female participants and their partners must be surgically sterile or on their chosen method of birth control as per the protocol.

Exclusion Criteria

  • Any evidence of diseases such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active interstitial lung disease/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations, history of uncontrolled or symptomatic cardiac disease, and history of allogenic organ transplant
  • Active or prior documented autoimmune or inflammatory disorders
  • History of another primary malignancy, except for malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study intervention
  • History of leptomeningeal carcinomatosis
  • History of active primary immunodeficiency
  • Known to have tested positive for human immunodeficiency virus [HIV] (positive HIV 1/2 antibodies) or active tuberculosis infection
  • Participants co-infected with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) or co-infected with HBV and Hepatitis D virus (HDV)
  • Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 1) caused by previous anticancer therapy
  • Central nervous system metastases requiring treatment or history of spinal cord compression
  • Known allergy or hypersensitivity to any of the study intervention or any of the study intervention excipients.
  • Any concurrent chemotherapy, other than the one allowed in the study, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment
  • Palliative radiotherapy with a limited field of radiation within 2 weeks of the first dose of study intervention, or radiotherapy with a wide field of radiation or radiotherapy affecting more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention
  • Major surgical procedure within 28 days prior to the first dose of IMP
  • Prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines
  • Receipt of the last dose of anticancer therapy within 28 days prior to the first dose of IMP

Get This Program In Your Inbox

You can sign up and apply your patients for this program.